Haptena Therapeutics has secured a €3 million seed funding from Claris Ventures to advance its innovative therapies for KRAS-mutant cancers.

Information on the Target

Haptena Therapeutics is a newly established biotechnology firm focused on innovating treatment strategies for genetically defined cancers. Announced on December 16, 2025, the company has successfully completed a €3 million seed financing round. This funding was provided by Claris Ventures, a venture capital firm based in Italy that specializes in early-stage biotech investments. Haptena's primary objective is to develop a discovery platform aimed at improving long-term patient outcomes for those affected by KRAS-mutant tumors, which currently have limited treatment options.

Founded by Professor Chiara Ambrogio of the University of Turin and Professor Roberto Chiarle from Boston Children’s Hospital and Harvard Medical School, Haptena leverages extensive expertise in cancer biology and tumor evolution. Their focus on precision oncology and the specific vulnerabilities of KRAS mutations positions them to make significant strides in treating these challenging cancers.

Industry Overview in Italy

Italy’s biotechnology sector has been rapidly evolving, supported by a strong research foundation and numerous academic institutions dedicated to life sciences. With a focus on innovative treatments, the indus